Kimia Biosciences Reports Strong Financial Performance in Q1 2024

Kimia Biosciences, a microcap pharmaceutical company, has recently announced its financial results for the quarter ending March 2024. The company has shown a positive performance in this quarter, with a score of 16 compared to -2 in the previous quarter.

The company's profit before tax (PBT) has seen a significant growth of 143.9% at Rs 2.01 crore, compared to the average PBT of the previous four quarters at Rs -4.58 crore. This shows a very positive trend in the near term for PBT.

Similarly, the profit after tax (PAT) has also shown a growth of 158.9% at Rs 1.80 crore, compared to the average PAT of the previous four quarters at Rs -3.06 crore. This indicates a very positive trend in the near term for PAT.

Kimia Biosciences has also shown a strong ability to manage its interest payments, with an operating profit to interest ratio of 3.10 times, the highest in the last five quarters.

The company's net sales for this quarter were at Rs 30.30 crore, the highest in the last five quarters, showing a positive trend in the near term. The net sales have also grown at 24.7% compared to the average net sales of the previous four quarters at Rs 24.31 crore.

The operating profit (PBDIT) for this quarter was at Rs 4.16 crore, the highest in the last five quarters, indicating a positive trend in the near term. The operating profit margin was also at its highest at 13.73%, showing an improvement in the company's efficiency.

Overall, Kimia Biosciences has shown a strong financial performance in the quarter ending March 2024, with positive trends in key areas such as PBT, PAT, net sales, and operating profit. This has resulted in a higher earnings per share (EPS) of Rs 0.38, indicating increasing profitability and creating higher earnings for shareholders. Based on these financial results, MarketsMOJO has given a 'Sell' call for Kimia Biosciences' stock.